.Johnson & Johnson’s deprioritization of its own transmittable health condition pipeline has actually declared yet another victim in the form of its dengue virus vaccine mosnodenvir.Mosnodenvir is actually developed to block communications in between pair of dengue virus healthy proteins. The vaccination endured J&J’s decision in 2014 to merge its transmittable condition as well as injection functions, which viewed the likes of a late-stage breathing syncytial virus program fell coming from the Major Pharma’s pipe and also an E. coli vaccination sold off to Sanofi.Mosnodenvir has actually had a rough time in the clinic, with J&J terminating one litigation because of the impact of COVID-19 on registration and pausing employment in an additional study in 2022.
Yet the loyalty to mosnodenvir appeared to pay off in October 2023, when the vaccine was revealed to generate a dose-dependent antiviral effect on the detectability as well as start of dengue infection serotype 3 in a period 2 test. That data decline does not appear to have actually sufficed to save mosnodenvir for long, with the Big Pharma announcing this morning that it is actually stopping a follow-up period 2 area research study. The decision is actually related to a “calculated reprioritization of the business’s infectious diseases R&D profile,” added J&J, which emphasized that no safety concerns had actually been actually recognized.” Johnson & Johnson are going to continue to support the aggression against dengue by sharing research results along with the clinical area down the road,” the pharma mentioned in the release.J&J had actually been buying dengue for over a decade, featuring releasing a Satellite Center for Global Health Finding at the Duke-NUS Medical College in Singapore in 2022.
The facility has been concentrated on increasing early-stage discovery investigation to “deal with the developing difficulty of flaviviruses” like dengue and Zika.